Mankind, BDR Pharma to distribute Baricitinib in India

62
Medicine Tablet
Picture: Pixabay

Last Updated on June 26, 2021 by The Health Master

Mankind Pharma has partnered with BDR Pharmaceuticals for distributing the anti-C-19 drug Baricitinib under the trademark Barikind that received restricted emergency use approval for use in combination with remdesivir, a company statement said.

According to the statement, under the partnership, BDR Pharma will be manufacturing and marketing the product under a royalty-free, limited and non-exclusive voluntary licence from Eli Lilly and Company, and Mankind Pharma will be distributing the same.

“Baricitinib received restricted emergency use approval for use in combination with remdesivir, for treatment of C-19 in hospitalised adults, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Lilly received permission for restricted emergency use from the Central Drugs Standard Control Organisation (CDSCO),” added the statement.

IPC to sensitize stakeholders on manufacturing of Quality Drugs

J Mitra and Company launches C-19 Microlisa Elisa Test kit

Mankind launches drug to treat Diabetes, Heart failure

Dr. Reddy’s Labs launches Icosapent Ethyl Capsules

Cadila Pharma launches Posaconazole to treat fungal diseases

European Commission approves Empagliflozin to treat heart failure

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner